Hepion Pharmaceuticals, Inc. (HEPA)

NASDAQ: HEPA · IEX Real-Time Price · USD
0.694
-0.007 (-1.07%)
At close: Jun 24, 2022 4:00 PM
0.700
+0.006 (0.937%)
After-hours: Jun 24, 2022 5:08 PM EDT
-1.07%
Market Cap 52.87M
Revenue (ttm) n/a
Net Income (ttm) -33.59M
Shares Out 76.23M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 118,101
Open 0.710
Previous Close 0.701
Day's Range 0.661 - 0.744
52-Week Range 0.610 - 2.318
Beta 1.41
Analysts Buy
Price Target 4.85 (+599.4%)
Earnings Date n/a

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor bur... [Read more...]

Industry Pharmaceuticals
CEO Robert Foster
Employees 20
Stock Exchange NASDAQ
Ticker Symbol HEPA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 599.35% from the latest price.

Price Target
$4.85
(599.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dr...

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellul...

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dr...

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –

Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug de...

CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and f...

Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug de...

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes -

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.

Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company's Strategic Med...

- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion's business development and partnering efforts in As...

Hepion Pharmaceuticals' Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic An...

Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer Anti-tumor activity observed in fatty livers suggests ...

Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431

EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug d...

Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference

EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug d...

Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference

- Oral Presentation Chosen as a “Distinguished” Abstract - - Oral Presentation Chosen as a “Distinguished” Abstract -

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

- New IND Expands Liver Disease Pipeline for CRV431 -

Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug d...

Anti-Cancer Mechanism of Hepion Pharmaceuticals' CRV431 Highlighted in Scripps Research Institute Poster at AASLD, Th...

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug d...

All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431

EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial. Related Content:   Hepion Pharma's NASH Candidate Aces Mid-Stage Study.

Why Are Hepion Pharma Shares Moving Higher Premarket Monday?

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today, Hepion will share additional data f...

Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in ...

EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols: LPTXNYMXVSTM

Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders

EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...

Hepion Pharma's NASH Candidate Aces Mid-Stage Study

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive topline results from its Phase 2a AMBITION NASH clinical trial evaluating CRV431, a potent inhibitor of cyclophilins. In the trial, CRV43...

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting

EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment o...